tiprankstipranks
Trending News
More News >

Hansoh Pharmaceutical Enters Strategic License Agreement with Regeneron

Story Highlights
Hansoh Pharmaceutical Enters Strategic License Agreement with Regeneron

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ).

Hansoh Pharmaceutical Group Company Limited has entered into a license agreement with Regeneron Pharmaceuticals, Inc., granting Regeneron an exclusive worldwide license to develop, manufacture, and commercialize the investigational drug HS-20094 outside of the Chinese Mainland, Hong Kong, and Macau. This agreement could potentially bring Hansoh up to $1.93 billion in milestone payments and double-digit royalties, enhancing its market position and leveraging its technology platforms. The agreement is seen as beneficial for Hansoh’s shareholders and aligns with the company’s strategic goals.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

More about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on developing and commercializing innovative medicines. The company operates in the biotechnology sector, primarily dealing with investigational drugs and therapies, with a significant focus on the Chinese market.

Average Trading Volume: 12,253,944

Technical Sentiment Signal: Buy

Current Market Cap: HK$153.7B

See more data about 3692 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1